PACE Framework Aims to Make Preemptive Pharmacogenomics Testing Routine
This perspective introduces the PACE framework, arguing that pharmacogenomic testing should be preemptive, adaptable, current, and executable to overcome barriers to clinical implementation. The key challenge is integrating gene-drug interaction data seamlessly into electronic health records at the point of prescribing. With testing costs now low and clinical practice guidelines available, the bottleneck has shifted from science to systems integration.
The original study
PACE Forward-Making Pharmacogenomics Testing Available for Real-Life Clinical Utility.
- Authors
- Lazaridis KN
- Journal
- Clinical pharmacology and therapeutics
- Type
- Journal Article, Research Support, Non-U.S. Gov't, Review
- PMID
- 30520030
Original abstract
Although pharmacogenomics (PGx) offers the promise of ensuring the right patient receives the right medication at the right dose the first time, gene-drug interaction data have yet to be seamlessly integrated into patients' health records. PGx testing that is preemptive, adaptable, current, and executable (PACE) overcomes the human and technological barriers to successful implementation, thus capitalizing on the affordable cost of such testing and clinical practice guidelines at the point of prescription ordering.